J&J (JNJ) Gets First Full Approval for COVID Jab in Canada

J&J JNJ announced that its adenovirus-based single-shot vaccine has been granted full approval by Health Canada for the prevention of COVID-19 disease in individuals 18 years of age and older.

J&J JNJ announced that its adenovirus-based single-shot vaccine has been granted full approval by Health Canada for the prevention of COVID-19 disease in individuals 18 years of age and older.